Welcome to the 6th Annual Gene Therapy for Rare Disorders Europe Summit 2022 - Gain European Regulatory Clarity to Progress Efficient & Robust Gene Therapies for Rare Disease

As more and more companies gear up for clinical activity and near approval decisions, the need to have an in-depth understanding of the regulatory frameworks and how these feed into clinical development and manufacturing processes is as vital as ever.

This year’s summit is dedicated to gaining European regulatory clarity to progress efficient and robust gene therapies for rare disease. By giving voice to pioneering drug developers with success stories to share, experts in regulatory affairs, and the regulators themselves, this meeting is your comprehensive guide to unpicking the thorniest regulatory challenges.

Across three carefully curated days, this streamlined one-track summit will unite key gene therapy leaders from large pharma to ground-breaking biotech, academics to exciting service providers, all with the purpose of paving a way forward to successfully launch gene therapy products in Europe.

Download the full event guide to see the complete speaking list and content in store for 2022.

World-Class Speaking Faculty

Christina Ohnsman

Senior Clinical Development Lead

REGENXBIO

Craig Martin

Chief Executive Officer

Global Genes

Mike Fraser

General Manager Europe, Middle East and Africa

Novartis Gene Therapies

Nicholas Medcalf

ISCF Deputy Challenge Director, Medicines Manufacturing

Innovate UK

Angela Columbano

Head, Business Development & Partnership

Genethon

Anne Douar

Chief Development Officer

Vivet Therapeutics

Magali Taiel

Chief Medical Officer

GenSight Biologics

Paolo Morgese

EU Director Market Access & Member Relations

Alliance for Regenerative Medicine (ARM)

Other Events in the Gene Therapy Series

Proud to Partner With

Thermo Fisher Scientific (003)
Capture
Capture
Primary Logo Light Background (002)